Trial Profile

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domvanalimab (Primary) ; Fluorouracil (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Zimberelimab (Primary)
Indications Carcinoid tumour; Carcinoma; Gastro-enteropancreatic neuroendocrine tumour; Gestational trophoblastic disease; Lung cancer; Malignant thymoma; Mesothelioma; Peritoneal cancer; Thoracic neoplasms; Thymoma; Thyroid cancer
Focus Therapeutic Use
Acronyms IMMUNORARE5

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com